Tag:
Tekturna
Latest Headlines
Latest Headlines
Indian panel accuses Big Pharma of colluding with regulators
An Indian government report has hit the domestic pharma business like a whirlwind--and sucked Big Pharma into the fury.
Novartis to revamp Rasilez label with safety risks
The data on Rasilez 's safety risks is coming home to roost. The Novartis ( $NVS ) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links...
Novartis ends Tekturna trial on safety concerns
Bad news for Novartis' ( $NVS ) blood pressure med Tekturna (aka Rasilez ). The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also
Blockbuster hopes for Rasilez fade at Novartis
Novartis' ( $NVS ) bid to expand the use of Rasilez has run into serious trouble. The pharma company joined the lineup of Big Pharma companies reporting trial setbacks today with the news that
FDA approves Novartis' combo pill Teklamo
The FDA has approved Teklamo, a high blood pressure medication that combines Tekturna with the calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely
Novartis: Tekturna doesn't help after heart attack
Novartis will not pursue an outcomes trial of its high blood pressure med Tekturna (aliskiren) in combination with standard therapy for heart attack patients after the drug failed to demonstrate a
Novartis buying Speedel for $880 million
Switzerland's Novartis has scooped up a majority of the shares of Speedel and plans to swiftly complete the purchase of all its stock in a deal valued at $880 million. At 130 francs per share,
ALSO NOTED: BMS to shutter Puerto Rico plant; Ranbaxy can launch copycat Imitrex;
> Bristol-Myers Squibb will close its plant in Barceloneta, Puerto Rico, as part of its ongoing restructuring efforts. About 225 people will lose their jobs with the closure.
Rasilez approval spurs Novartis expansion
Bolstered by the EU's blessing on its new hypertension treatment Rasilez, Novartis is planning a €183 million ($250 million) expansion of a plant near Basel, Switzerland. The expansion will boost
